Canakinumab Treatment in Familial Mediterranean Fever Patients: With/Without Colchicine
International Journal of Rheumatic Diseases · 2025-03 · 28 (3)
DOI: 10.1111/1756-185x.70159 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 05.03.2025. Verfasst von Tahir Saygın Öğüt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Antalya City Hospital, Antalya, Turkey. Hauptthemen laut MEDLINE: Colchicine, Familial Mediterranean Fever, Antibodies, Monoclonal, Humanized, Kidney. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
To compare the differences in attack characteristics, acute‐phase reactants, and renal outcomes in patients using canakinumab with or without colchicine treatment.
Methods
FMF patients treated with canakinumab for ≥ 3 months were retrospectively reviewed. Patients unable to continue colchicine for various reasons were identified and grouped as those receiving the canakinumab + colchicine combination (CAN + CLC) and canakinumab monotherapy (CANmono). Attack frequency, C‐reactive protein (CRP), urine protein–creatinine ratio (UPCR), and kidney function tests were recorded before and after canakinumab treatment.
Results
Fifty‐five patients receiving canakinumab treatment were included in the study. Thirty‐one patients (56.4%) used CAN + CLC and 24 (43.6%) CANmono. With both CAN + CLC and CANmono treatment, there was no significant change in UPCR of patient groups with GFR > 60 and < 60 mL/min/1.73 m 2 . Amyloid A (AA) amyloidosis was present in 21 (38.2%) patients. In patients with AA amyloidosis receiving CAN + CLC, there was a nonsignificant decrease in UPCR and increased creatinine levels after treatment ( p = 0.214 and p = 0.051, respectively). Median GFR decreased significantly from 69 (IQR, mg/dl, 45–95) to 44 (IQR, mg/dl, 28–75) with CAN + CLC treatment ( p = 0.021). In the CANmono group, compared to baseline values, there was no significant change in posttreatment UPCR, serum creatinine, and GFR values.
Conclusion
It is difficult to make a recommendation regarding the discontinuation or continuation of colchicine treatment in all FMF patients who initiated anti‐IL‐1 treatment. Canakinumab can be continued as monotherapy in patients who cannot continue colchicine treatment due to side effects and patient noncompliance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Antalya City Hospital, Antalya, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Akdeniz University, Antalya, Turkey.
- Department of Rheumatology, Edirne Sultan 1. Murat State Hospital, Edirne, Turkey.
ORCID-Profile: Tahir Saygın Öğüt, Funda Erbasan
Zitieren
APA
Öğüt, T. S., Yazisiz, V., Dilbil, M., Nokay, M., Terzioğlu, M. E., & Erbasan, F. (2025). Canakinumab Treatment in Familial Mediterranean Fever Patients: With/Without Colchicine. International Journal of Rheumatic Diseases, 28(3). https://doi.org/10.1111/1756-185x.70159
Vancouver
Öğüt TS, Yazisiz V, Dilbil M, Nokay M, Terzioğlu ME, Erbasan F. Canakinumab Treatment in Familial Mediterranean Fever Patients: With/Without Colchicine. International Journal of Rheumatic Diseases. 2025;28(3). doi:10.1111/1756-185x.70159
BibTeX
@article{t2025,
author = {Öğüt, Tahir Saygın and Yazisiz, Veli and Dilbil, Melis and Nokay, Mine and Terzioğlu, Mustafa Ender and Erbasan, Funda},
title = {Canakinumab Treatment in Familial Mediterranean Fever Patients: With/Without Colchicine},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
volume = {28},
number = {3},
doi = {10.1111/1756-185x.70159}
}
EUVIMED